Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-25T05:31:40.723Z Has data issue: false hasContentIssue false

Uptake and initial use of novel antimicrobial agents at community hospitals in western Pennsylvania

Published online by Cambridge University Press:  22 August 2019

J. Ryan Bariola*
Affiliation:
Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
T. Khadem*
Affiliation:
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
M. Hong Nguyen
Affiliation:
Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
*
Author for correspondence: J. Ryan Bariola, MD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: bariolajr@upmc.edu. Or T. Khadem, PharmD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: khademt@upmc.edu
Author for correspondence: J. Ryan Bariola, MD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: bariolajr@upmc.edu. Or T. Khadem, PharmD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: khademt@upmc.edu

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Brief
Copyright
© 2019 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. This study was presented as an abstract at ID Week 2018 on October 6, 2018 in San Francisco, California.

References

Schulz, LT, Kim, SY, Hartsell, A, Rose, WE. Antimicrobial stewardship during a time of rapid antimicrobial development: potential impact on industry for future investment. Diagn Microbiol Infect Dis 2019. pii: S0732-8893(19)30344-X. Advance online publication.Google Scholar
Shields, RK, Potoski, BA, Haidar, G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016;63:16151618.CrossRefGoogle ScholarPubMed
Gelfand, MS, Cleveland, KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2015;61:853855.CrossRefGoogle ScholarPubMed
Delaportas, DJ, Estrada, SJ, Darmelio, M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy 2017;37:e90e92.CrossRefGoogle ScholarPubMed
Shields, RK, Nguyen, MH, Chen, L, Press, EG, Kreiswirth, BN, Clancy, CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infection. Antimicrob Agent Chemother 2018;62:e0249717.CrossRefGoogle Scholar
Plant, AJ, Dunn, A, Porter, RJ. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Psuedomonas aeruginosa pneumonia. Expert Rev Anti Infect Ther 2018;16:367368.CrossRefGoogle Scholar
Cox, E, Nambiar, S, Badan, L. Needed: antimicrobial development. New Eng J Med 2019;380:783785.CrossRefGoogle ScholarPubMed
Antibacterial therapies for patients with an unmet need for the treatment of serious bacterial diseases guidance for industry. US Food and Drug Administration website. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM359184.pdf Published August 2017. Accessed February 18, 2019.Google Scholar